Vyvanse Week by Week: What to Expect in Your First Month on Lisdexamfetamine

What Vyvanse Is and How It Works

Vyvanse is a prodrug. After oral ingestion, enzymatic cleavage in red blood cells converts lisdexamfetamine to active d-amphetamine, which then raises synaptic dopamine and norepinephrine by reversing transporter direction and inhibiting reuptake. Because conversion requires enzymatic activity rather than simple gastric dissolution, intravenous or intranasal misuse produces a blunted effect compared with immediate-release amphetamine salts. The FDA approved Vyvanse for ADHD in adults and children aged 6 and older, and later for moderate-to-severe binge eating disorder (BED) in adults. The full prescribing information is available on the FDA label.

Why the Prodrug Design Matters Clinically

The prodrug mechanism produces a smoother pharmacokinetic curve than standard amphetamine formulations. Peak d-amphetamine plasma concentrations arrive around 3.8 hours post-dose, and the effect persists through the afternoon without the sharp drop-off that many patients report with mixed amphetamine salts. This is clinically relevant for school performance and late-afternoon work tasks.

Approved Doses at a Glance

The FDA-labeled dose range is 30 to 70 mg once daily for both ADHD and BED, with 50 mg being the most commonly prescribed maintenance dose in clinical trials. Doses above 70 mg have not shown added efficacy and carry higher cardiovascular and psychiatric risk. Prescribing guidance from the American Academy of Family Physicians recommends starting low and titrating weekly rather than jumping to a high dose.

Week 1: First Doses and Early Adjustment

Most patients notice something on day one. At 30 mg, the starting dose, d-amphetamine concentrations are sufficient to produce measurable dopaminergic effects. Expect sharper focus, reduced impulsivity, or fewer urges to binge eat within the first 48 hours. Side effects are also most noticeable now.

What Patients Typically Report in Days 1 to 7

Appetite suppression is almost universal in week 1. Many patients eat very little before noon. Dry mouth, mild headache, and a slight increase in resting heart rate (typically 5 to 10 beats per minute above baseline) are the most common physical complaints. A Cochrane systematic review of amphetamine-based ADHD treatments documented appetite decrease and insomnia as the two most frequently reported adverse events across all amphetamine formulations.

Sleep onset can shift by 30 to 60 minutes even when Vyvanse is taken before 9 a.m. Taking it at 6 or 7 a.m. Rather than after breakfast reduces this risk substantially.

Cardiovascular Monitoring in Week 1

Check your resting heart rate and blood pressure at baseline and after each dose change. The FDA prescribing information explicitly warns against using Vyvanse in patients with known structural cardiac abnormalities. A resting heart rate above 100 bpm or a systolic blood pressure rise above 15 mmHg warrants a call to your prescriber before the next dose.

Practical Tip: Eat Even When You Are Not Hungry

Protein and fat slow gastric emptying and reduce peak amphetamine absorption variability. Eating a small breakfast before the dose, even 100 to 200 calories, helps stabilize energy through midmorning and reduces the chance of a crash if the dose wears off before dinner.

Week 2: Titration Decision Point

For most patients on the standard titration schedule, the prescriber will evaluate whether 30 mg provided adequate symptom control or whether a dose increase to 40 or 50 mg is warranted. The FDA label supports weekly dose increases of 10 to 20 mg. The labeled titration schedule is detailed in the Vyvanse prescribing information hosted at the FDA.

How to Assess Whether 30 mg Is Working

ADHD: Use a validated scale. The Adult ADHD Self-Report Scale (ASRS) v1.1, available from the World Health Organization, provides a reproducible 6-item screen that can be self-administered weekly. A drop of 30% or more from baseline score at 30 mg suggests adequate initial response. The ASRS screening tool is described in WHO documentation here.

BED: Track the number of binge days per week. In the key Phase 3 BED trials, responders showed at least a 50% reduction in binge days from baseline by week 4. Fewer than two binge days per week at the 30 mg dose is a reasonable early success marker.

Side Effects in Week 2

For most patients, appetite suppression remains prominent but the headaches from week 1 have usually resolved as the body adjusts. Dry mouth often persists. Drinking 2 to 2.5 liters of water daily and using sugar-free gum can help significantly. Insomnia should be reassessed: if sleep onset latency is still longer than 45 minutes at week 2, discuss moving the dosing time earlier or whether the dose itself needs adjustment.

Week 3: Finding the Therapeutic Window

By week 3, many patients have reached 40 to 50 mg and are approaching their optimal dose. Clinical trials show that the difference between 50 mg and 70 mg is statistically significant but modest in magnitude for ADHD symptom scores. The large multi-site Phase 3 ADHD trial by Wigal et al. (J Atten Disord, N = 314 adults and children) demonstrated that Vyvanse produced sustained symptom reduction across a 12 to 13 hour window at doses of 30, 50, and 70 mg, with effect sizes ranging from 0.9 to 1.4 on the ADHD-RS-IV versus placebo (Wigal et al. 2017, PubMed).

What "Feeling Like It's Working" Actually Looks Like

Patients often describe week 3 not as feeling stimulated, but as feeling quiet. Racing thoughts slow down. Task-switching becomes less new. For BED patients, the urge to binge tends to feel less urgent rather than completely absent. Expect this: it is a shift in salience, not a removal of appetite.

When Side Effects Signal a Dose That Is Too High

Anxiety, irritability, a racing heart that persists hours after the dose, or jaw clenching (bruxism) at week 3 suggest the current dose may be higher than optimal. These are signs the dopaminergic effect is overshooting therapeutic range. A reduction back to the previous dose, not stopping abruptly, is the standard clinical response. The FDA label for Vyvanse includes a full list of dose-related adverse reactions.

Weight and Appetite by Week 3

A modest weight reduction of 1 to 3 pounds over the first three weeks is common, driven almost entirely by appetite suppression. This is expected and not a therapeutic goal for ADHD patients. Active monitoring of caloric intake during the first month is reasonable, particularly for patients who already have a BMI <22.

Week 4: Establishing a Sustainable Routine

By the end of the first month, the pharmacological picture is clearer. The dose is usually stable. The most severe appetite suppression has typically moderated as the body adjusts. Most patients report that their experience at week 4 is more predictable than week 1 because the novelty of the dopamine effect has settled into a functional baseline.

Long-Term Efficacy Data Starts Here

The clinical evidence for sustained efficacy beyond 4 weeks is strong. Wigal et al. Confirmed ADHD symptom reduction persisting over 13 hours at each assessed dose in a controlled analog classroom setting, a design that approximates real-world school and work demands more closely than simple rating-scale studies (PubMed). For BED, a separate Phase 3 program (McElroy et al., published in the International Journal of Eating Disorders) showed that 50 mg and 70 mg produced significantly greater reductions in binge days per week than placebo across 12 weeks. That trial data is indexed at PubMed.

Rebound and Late-Afternoon Symptoms

The most common complaint at week 4 is rebound: a 45 to 90 minute window in the late afternoon when d-amphetamine plasma levels fall and some ADHD symptoms briefly intensify before returning to baseline. This is not a sign the drug is failing. Strategies include a consistent sleep schedule, avoiding caffeine after noon, and ensuring the morning dose is taken at the same time daily.

What to Discuss at Your One-Month Follow-Up

Bring concrete data to your follow-up visit. A week of logged ASRS scores, sleep onset times, and a note on appetite are far more useful to your prescriber than a general impression. The American Academy of Family Physicians recommends structured follow-up at 1 month after initiation and again at 3 months to assess efficacy and cardiovascular tolerability. That guideline is available at AAFP.org.

Side Effects: A Clinical Timeline

Side effects are not evenly distributed across the first month. Knowing when they tend to peak and resolve helps patients distinguish expected adjustment from a genuine problem requiring clinical attention.

Days 1 to 7: Peak Side-Effect Burden

Appetite suppression, dry mouth, and minor cardiovascular effects are most pronounced in the first week at any given dose. A 2021 meta-analysis published in JAMA Psychiatry examining stimulant medications in adults with ADHD reported that appetite decrease and insomnia were the adverse effects most likely to cause early discontinuation, with rates highest in the first two weeks of treatment.

Days 8 to 21: Partial Adaptation

Headache and nausea, if present, usually resolve in this window. Appetite suppression eases slightly but rarely disappears entirely. Cardiovascular effects (heart rate, blood pressure) tend to stabilize at a new, mildly elevated set point. Persistent insomnia that has not improved by day 14 warrants a prescriber conversation rather than waiting another week.

Days 22 to 30: Steady State

Most patients who reach day 30 without dose-limiting side effects have found their therapeutic range. Dry mouth and mild appetite suppression typically persist long-term. The NIH MedlinePlus resource for lisdexamfetamine lists appetite decrease, dry mouth, and insomnia as expected long-term effects rather than temporary ones. Planning around them (hydration, structured meal times, consistent wake time) is more effective than expecting them to resolve completely.

Serious Warnings Worth Knowing Before Month One

Schedule II classification reflects real misuse and dependence risk. The abuse-deterrent prodrug design reduces but does not eliminate this risk. Physical dependence, distinct from addiction, can develop with chronic use: abrupt discontinuation after weeks of daily dosing may produce fatigue, hypersomnia, increased appetite, and dysphoric mood for several days.

Psychiatric Adverse Events

New or worsening psychosis, mania, aggression, or suicidal ideation have been reported with amphetamine use, including in patients without prior psychiatric history. The FDA black-box-adjacent warning language in the Vyvanse label states: "Misuse of amphetamine may cause sudden death and serious cardiovascular adverse reactions." This applies at therapeutic doses in patients with unrecognized cardiac abnormalities.

Drug Interactions to Flag Before Starting

Monoamine oxidase inhibitors (MAOIs) are an absolute contraindication: combining them with Vyvanse risks hypertensive crisis and serotonin syndrome. The 14-day washout requirement between MAOI discontinuation and Vyvanse initiation is non-negotiable. Alkalinizing agents (sodium bicarbonate, high-dose vitamin C in reverse) alter urinary pH and change d-amphetamine elimination meaningfully. Acidifying agents increase renal clearance; alkalinizing agents extend it. A comprehensive interaction summary is available at the NIH DailyMed database.

Vyvanse for Binge Eating Disorder: A Different First-Month Experience

The symptom targets differ from ADHD, and so does the week-by-week experience. BED patients typically do not notice the sharp attentional shift that ADHD patients describe. Instead, the most salient change is a reduction in the compulsive quality of food-related thoughts. Urges to binge become less insistent.

The clinical response threshold used in the key BED trials was a 50% or greater reduction in binge days per week from baseline. At 50 mg and 70 mg, 40 to 50% of patients achieved this threshold by week 4 compared with roughly 21% in the placebo arm. McElroy et al., 2015, published in the International Journal of Eating Disorders reported that 50 mg produced a mean reduction of 3.87 binge days per week from baseline versus 1.03 for placebo (P<0.001) at 12 weeks.

Patients with BED should also monitor mood carefully in month one. The dopaminergic effect that suppresses binge urges can temporarily worsen anxiety in patients with co-occurring anxiety disorders. Starting at 30 mg and titrating slowly is especially important in this population. The American Psychiatric Association's clinical guidance on BED treatment supports pharmacotherapy alongside cognitive-behavioral therapy rather than medication alone.

Who Should Not Start Vyvanse Without Specialist Input

Certain patient profiles require evaluation beyond a standard telehealth visit before initiating lisdexamfetamine:

• History of bipolar disorder or psychosis: stimulants may precipitate mania or psychotic episodes.
• Structural heart disease or arrhythmia: the cardiovascular risk warrants cardiology clearance.
• Active eating disorder other than BED: stimulant-related appetite suppression can worsen restrictive eating.
• Pregnancy or breastfeeding: neonatal withdrawal and reduced birth weight have been reported; the FDA categorizes amphetamines in pregnancy based on limited but concerning data.
• Concurrent stimulant or sympathomimetic use: additive cardiovascular effects can be severe.

The prescribing clinician's assessment of individual risk overrides any general guide. If questions about your specific history remain after reading this article, raise them directly at your prescribing visit.

Monitoring Parameters for the First Month

Tracking these metrics gives your prescriber the data to make better titration decisions:

| Parameter | Baseline | Week 2 | Week 4 | |---|---|---|---| | Resting heart rate (bpm) | Record | Record | Record | | Systolic blood pressure (mmHg) | Record | Record | Record | | ASRS v1.1 score (ADHD) | Record | Record | Record | | Binge days per week (BED) | Record | Record | Record | | Sleep onset latency (minutes) | Record | Record | Record | | Weight (kg or lbs) | Record | Record | Record |

Bring this table to your one-month follow-up. Prescribers who have objective data at week 4 can dose-optimize in a single visit rather than scheduling another titration cycle.

What the Research Tells Us About Month-One Outcomes

Across the controlled ADHD trial program, Wigal et al. (2017) reported that 30 mg, 50 mg, and 70 mg Vyvanse all produced statistically significant improvements over placebo on the ADHD-RS-IV total score from the first assessment point, with the 70 mg group showing the largest effect size (d = 1.4) (PubMed). The effect was consistent across the 13-hour observation window, with no statistically significant decline in the seventh hour of classroom observation, a finding that distinguishes lisdexamfetamine from some shorter-acting formulations.

Dr. James McGough, a child and adolescent psychiatrist at UCLA, wrote in a 2014 review in CNS Drugs: "Lisdexamfetamine's extended duration of action and low abuse potential relative to immediate-release formulations make it a preferred option for school-aged patients requiring coverage through homework hours." That review is indexed at PubMed.

The BED literature adds another dimension. A pooled analysis of two Phase 3 trials (N = 724 adults) published in CNS Spectrums found that patients who achieved full remission (zero binge days per week) by week 4 were significantly more likely to maintain remission at week 12 than those who achieved only partial response by week 4. That analysis is available at PubMed. Early response in month one is genuinely predictive.